European Cancer Organisation
login

Call for Abstracts

 

**ABSTRACT SUBMISSION IS NOW CLOSED**

Deadline: Thursday, 9 February 2017 (23:59 CET)


Abstract Regulations

With the submission of an abstract to EAS2017, the first author (presenting author):

  • Accepts responsibility for the accuracy of the submitted abstract.
  • Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
  • Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
  • States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
  • Gives permission for the abstract, when selected for presentation (oral or poster), to be published in the Conference Proceedings. 
  • Encore abstracts will be accepted.
  • Submitted abstracts cannot be withdrawn after 03 March 2017.

 

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

  • The abstract must be submitted in good English.  The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
  • Abstract titles should be brief and should reflect the content of the abstract.
  • Commercial names may not be used in the abstract title.
  • No more than 10 authors can be listed.  Only institutional affiliations, cities and countries should follow.  
  • Abstracts on “trials in progress” can be submitted and will be considered for oral or poster presentation as long as they contain at least some preliminary and presentable results. The decision regarding inclusion in the programme and type of presentation will be decided by the Scientific Programme Committee.
  • Abstracts should be organised under the headings:
    • Introduction
    • Material and method
    • Results and discussion
    • Conclusion
  • The online abstract submission procedure will not accept abstracts that exceed 2,500 characters (body of the abstract)
  • Abbreviations may be used if standard or if spelled out and defined at the first use.  Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
  • Supplementary data or appendices will not be accepted.
  • Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black.

Only the submitting author will receive a confirmation/abstract number by e-mail from the EAS2017 Conference Secretariat within 48 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.

For questions regarding the online submission process please contact Anne Blondeel, E-mail: anne.blondeel@@ecco-org.eu

 

Abstract Selection Process

The Scientific Committee will make the selection of abstracts for oral and poster presentations by early March 2017.

Middle of March 2017, the first author (presenter) will be notified about the result of the review and the Scientific Committee’s decision on the abstract.

If a selected author cannot attend, the presenting author should assign a replacement.

The following presentation formats are applicable for EAS2017:

  1. Oral presentation: the abstract is selected for oral presentation in a main programme symposium
  2. Poster presentation: an abstract that has been selected for presentation in poster format.  Posters are grouped by topic and will be displayed during specific Poster Sessions.

NB: If the abstract is accepted for oral or poster presentation, the abstract will only be published in the Proceedings Book if one of the authors is a registered participant and full payment has been received by the advised deadline.

 

Abstract Submission

Abstracts must be submitted on-line, from 01 November 2016 to 06 February 2017, via the conference website.

  • Please follow the instructions on the screen to submit your abstract.
  • If you do not receive any confirmation within 48 hours, please contact Anne Blondeel (anne.blondeel@@ecco-org.eu) within one week following the submission of the abstract.
  • Submitting an abstract for EAS2017 does not constitute registration for the conference. Abstract presenters must register to attend EAS2017 by following the instructions for registration on the website.

For questions regarding the on-line submission process, contact anne.blondeel@@ecco-org.eu

Only abstracts submitted online can be accepted. Abstracts submitted on paper or by e-mail attachment will not be considered.

 

Topics for Abstract Submission

  1. CELL AND TUMOUR BIOLOGY
    • Cell Proliferation/cell cycle
    • Cell Death / Autophagy
    • Oncogenes and Tumour Suppressor Genes
    • Tumour Progression: Invasion and Metastasis
    • Metastases and EMT
    • Tumour Microenvironment
    • Tumour Angiogenesis
    • Tumour Immunology AND Inflammation
    • Aging and Cancer
    • Senescence
    • Cancer Cell Metabolism
    • Cancer Initiating Cells / Cancer Stem Cells
    • Tumour heterogeneity
  2. CANCER GENOMICS, EPIGENETICS and GENOMIC INSTABILITY
    • Genomic Alterations in Cancer
    • Functional  Genomics
    • Epigenetic mechanisms and RNA
    • Genetic instability
    • Deep sequencing
  3. SIGNALING PATHWAYS
    • Receptors and Signal Transduction
    • Gene Expression, Transcriptional Regulation
    • Systems biology
    • Computational models of biological systems
    • Omics technologies
  4. CARCINOGENESIS
    • Mutagenesis, Carcinogen Metabolism
    • Promotion and Progression
    • DNA Damage and Repair
    • Viral Oncogenesis
  5. TRANSLATIONAL RESEARCH
    • Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment
    • Molecular pathology
    • Biomarkers with clinical relevance, imaging
    • Prognostic biomarkers of therapy response
    • Prognostic value of oncogenomics
    • Clinical Phase I/II trials with targeted drugs and novel agents
    • Bioinformatics in therapies and clinical trials
    • Animal models of cancer
    • Infrastructures (biobanks, databases, genomic resources, others)
  6. EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
    • Drug Discovery / Drug Design
    • Novel Targets, Delivery Systems
    • Mechanisms of Drug Action, Drug Profiling
    • Drug Resistance
    • Novel Approaches to Diagnosis of Cancer
    • New Therapies
    • Companion diagnostics
    • Personalized medicine
  7. TUMOUR IMMUNOLOGY
    • Tumour Immunology
    • Immune Suppression and Escape
    • Tumor antigens and immune effectors
    • Immunotherapy and Cancer Vaccines
    • Cancer vaccines: preclinical and clinical studies
  8. RADIOBIOLOGY / RADIATION ONCOLOGY
    • Tumour Cell Sensitization to Radiotherapy
    • Radiation-activated Signaling Pathways
    • Cell Cycle and Apoptosis in Radiation  Responses
    • Radiation Oncology; Preclinical and Clinical
    • Translational radiation research
  9. MOLECULAR AND GENETIC EPIDEMIOLOGY
    • Risk Factors
    • Biomarkers
    • Risk Assessment
    • Susceptibility Genes
    • Genotype / Phenotype Correlations
    • Genetic Polymorphisms and Cancer Susceptibility
    • Epidemiology 
  10. PREVENTION and EARLY DETECTION
    • Preclinical Prevention Studies, Markers and Prevention
    • Clinical Prevention Studies
    • Vaccination Against Cancer
  11. MOUSE MODELS
    • Transgenic models
    • Chemical carcinogenesis
    • PDXs
    • Humanised mouse models
  12. OTHER

 

PRINT THIS PAGE Page last modified: